Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics

J Clin Pharmacol. 2017 Nov;57(11):1454-1459. doi: 10.1002/jcph.964. Epub 2017 Jul 18.
No abstract available

Keywords: eluxadoline; hepatic impairment; irritable bowel syndrome; pharmacokinetics; safety.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Gastrointestinal Agents / adverse effects
  • Gastrointestinal Agents / blood
  • Gastrointestinal Agents / pharmacokinetics*
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Imidazoles / adverse effects
  • Imidazoles / blood
  • Imidazoles / pharmacokinetics*
  • Imidazoles / therapeutic use
  • Liver Diseases / blood
  • Liver Diseases / metabolism*
  • Male
  • Middle Aged
  • Phenylalanine / adverse effects
  • Phenylalanine / analogs & derivatives*
  • Phenylalanine / blood
  • Phenylalanine / pharmacokinetics
  • Phenylalanine / therapeutic use
  • Treatment Outcome
  • Young Adult

Substances

  • Gastrointestinal Agents
  • Imidazoles
  • eluxadoline
  • Phenylalanine